We conducted a pilot study wherein serum Glutathione-S-transferase levels were measured before and after radiotherapy in carcinoma cervix patients and correlated with response to treatment dudng a two-year follow-up period. Out of 17 patients who received radiotherapy, 9 showed a significant decrease (p< 0.005) while 8 showed significant increase (p< 0.004) in post radiotherapy glutathione-S-transferase values as compared to pre treatment values respectively. These patients were followed up for two years and we observed that 71% who had significant increase in post radiotherapy values had relapse of cancer within 2 years where as 66% of those who had significant decrease in post radiotherapy values had no evidence of relapse. This shows that alterations in serum Glutathione-Stransferase levels may help us to predict radiation response
INTRODUCTION

Alterations in circulating antioxidants and free radical scavengers have been linked with various epithelial malignancies(I-4). Many studies have shown a link
between altered expression of glutathione-Stransferase (GST) in plasma as well as in tissue biopsy samples from carcinoma cervix (5) (6) (7) (8) (9) . Radiotherapy (RT) is an important modality of treatment in carcinoma cervix. Response to RT may be good (with tumor regression and no relapse) or poor with relapse. We conducted a pilot study wherein we measured serum GST levels before and after RT in carcinoma cervix patients (10) (11) (12) (13) (14) (15) . The aim was to determine whether post RT GST levels as compared to pre RT levels had a relevance to relapse during the two year follow up pedod.
MATERIALS
Reduced glutathione C~0H1706S and 1-chloro-2,4,dinitro benzene (CDNB) were purchased from Sigma Chemical Company. All other reagents used were of Reagent grade. Deionized water was used throughout the study.
Serum GST levels were measured in biopsy proven
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Department of Biochemistry Kasturba Medical College, Manipal -576 104 Kamataka, India. 37 cases of carcinoma cervix and in age matched 10 healthy woman volunteers after obtaining proper permission. In cases blood was withdrawn just before initiation of any definitive treatment. In patients who received RT (n=17), GST was again estimated one day alter the last dose. Clinical response to treatment was evaluated in terms of tumor regression and evidence of relapse in 2-year follow up period.
METHODS
Serum GST was estimated by CDNB method (16) (17) (18) . c. GSH: 20mM in deionized water freshly prepared just before the assay. d. Serum: Blood was collected without any anticoagulant and allowed to clot for 1 hr. Clotted sample was centrifuged at 3500 rpm x 30 min at 4~ (in cold centrifuge). Serum was separated and stored at 4~ until use.
Assay
GST was estimated in lml of incubation mixture containing 850 pl of 0.1 M phosphate, buffer pH 6.5 CDNB reagent (20 mM) 50 pl, preincubated at 37~ for 10 min. Reaction was started by adding 50pl of 20 mM GSH and 50pl of serum. Reaction was followed at 1 rain intervaI for 5 rain by measuring absorption at 340 nm. Simultaneously, blank was run by substituting deoinized water for serum. Then O.D change/min was calculated. GST was estimated by using the molar extinction coefficient [9.6 mM -1 cm "1] of GST (17) .
Formula:
O.D or test -O.D of blank 9.6 x 0.05
RESULTS
X 1000 IU/Itr
The serum GST was not significantly altered in cases as compared to controls (Table-1). Out of 17 patients who received RT, 9 showed significant decrease (p<0.005), while others (n=8) significant increase (p<0.004) in post RT GST levels as compared to pre RT revels respectively (Table-2). We followed up these patients for next 2 years. We observed that, 71% of patients, who had significant increase in post RT GST, had relapse within 2 years and 66% of patients who had significant fall in post RT GST, had no evidence of relapse.
DISCUSSION
GST was chosen because of its proven association with poor prognosis and therapy resistance in other malignancies (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Relation between drug resistance and GST levels has been reported by many studies in various cancers (4, 11, 15, 19, 26, 27) . Association of GST and radiation resistance was reported by Agarwal et al (24) , KhU et al (25) and many others (11, 14, 19, 20, 22, 23, 28) . Radiotherapy is the primary modality of treatment in carcinoma cervix. There is no single marker available to predict the response to radiotherapy. Here we estimated GST before and just after the completion of radiotherapy. Radiation is known to induce oxidative stress, which may cause induction of antioxidant status of irradiated tumor (24) . This may influence the radiation response in some selected human caminoma cells (25) . Our results show an association of GST level and radiation response. But this cannot be generalized because our study group was small. We are planning to continue this study further to evaluate whether post radiotherapy GST values are helpful in predicting the radiation response. 
